| __timestamp | MiMedx Group, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7050000 | 46425000 |
| Thursday, January 1, 2015 | 8413000 | 81491000 |
| Friday, January 1, 2016 | 12038000 | 94291000 |
| Sunday, January 1, 2017 | 17900000 | 121827000 |
| Monday, January 1, 2018 | 15765000 | 160524000 |
| Tuesday, January 1, 2019 | 11140000 | 200000000 |
| Wednesday, January 1, 2020 | 11715000 | 275000000 |
| Friday, January 1, 2021 | 17344000 | 328100000 |
| Saturday, January 1, 2022 | 22829000 | 463800000 |
| Sunday, January 1, 2023 | 12665000 | 565000000 |
Infusing magic into the data realm
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. has consistently outpaced MiMedx Group, Inc. in R&D investment. From 2014 to 2023, Neurocrine's R&D expenses surged by over 1,100%, peaking at $565 million in 2023. In contrast, MiMedx's R&D budget grew by approximately 80%, reaching $22.8 million in 2022 before a slight dip in 2023.
This stark difference highlights Neurocrine's aggressive pursuit of new therapies, while MiMedx maintains a more conservative approach. The data underscores the importance of R&D in driving innovation and maintaining competitive advantage in the biotech sector. As the industry continues to grow, these investments will likely play a pivotal role in shaping the future of healthcare.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Neurocrine Biosciences, Inc. or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Research and Development Investment: PTC Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and MiMedx Group, Inc.
R&D Spending Showdown: Xencor, Inc. vs MiMedx Group, Inc.